Advertisement

MDL-17,043 (Piroximone)

  • Adam Schneeweiss
  • Gotthard Schettler
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 72)

Abstract

MDL-17,043, a new drug combining positive inotropic and peripheral vasodilatory properties, was found to be effective in treatment of congestive heart failure. It is available in intravenous as well as oral forms. Until its introduction, the overall hemodynamic effects of MDL-17,043 could have been achieved only with a combination of conventional agents. It therefore simplifies therapy in congestive heart failure and may improve elderly patients’ compliance. Since the mechanism of the positive inotropic effect of MDL-17,043 differs from those of digitalis glycosides and sympathomimetic amines, it is possible that unlike these agents the effect of MDL-17,043 will not decline with age.

Keywords

Congestive Heart Failure Cardiac Index Systemic Vascular Resistance Pulmonary Capillary Wedge Pressure Hemodynamic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dage RC, et al: Cardiovascular properties of a new cardiotonic agent: MDL-17,043 (1,3-dihydro-4-methyl–5–4-(methylthio)-benzoyl.-2H-imidazol-2-one). J Cardiovasc Pharmacol 4:500, 1982.PubMedCrossRefGoogle Scholar
  2. 2.
    Roebel LE, et al: Selective inotropic activity of RMI-17,043 in anesthetized and conscious dogs. Fed Proc 41:1310, 1982.Google Scholar
  3. 3.
    Investigational Brochure RMI 17,043, Merrell-Dow Research Center, Merrell Dow Pharmaceuticals Inc, Cincinnati, Ohio, 1981.Google Scholar
  4. 4.
    Kariya T, et al: Biochemical studies on the mechanism of cardiotonic activity of MDL-17,043: possible involvement of cyclic AMP phosphodiesterase inhibition. J Cardiovasc Pharmacol 4:509, 1982.PubMedCrossRefGoogle Scholar
  5. 5.
    Uretsky BF, et al: The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. Circulation 67:823, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Kereiakes DJ, et al: Mechanisms of improved left ventricular function with MDL-17,043 in heart failure [abstr]. Circulation 68:III–373, 1983.Google Scholar
  7. 7.
    Amin D, et al: Comparative hemodynamic effects of dobutamine and MDL 17,043 in congestive heart failure [abstr]. Circulation 68:III–120, 1983.Google Scholar
  8. 8.
    Amin DK, et al: Comparative acute hemodynamic effects of intravenous sodium nitroprus-side and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure. Am Heart J 109:1006, 1985.PubMedCrossRefGoogle Scholar
  9. 9.
    Uretsky BF, et al: Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure. Am J Cardiol 54:357, 1984.PubMedCrossRefGoogle Scholar
  10. 10.
    Petein M, et al: Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure. J Am Coll Cardiol 4:364, 1984.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1988

Authors and Affiliations

  • Adam Schneeweiss
    • 1
  • Gotthard Schettler
    • 2
  1. 1.Geriatric Cardiology Research FoundationTel-AvivIsrael
  2. 2.Department of MedicineUniversity of HeidelbergGermany

Personalised recommendations